Cat allergy vax looks promising; Philip Morris buys stake in Medicago; Nobel Prize-winner dies;

Vaccine Research

Although allergy shots have been available for years, scientists may have found an alternative treatment requiring far fewer shots. A clinical trial that Adiga Life Sciences' cat allergy vaccine showed no serious side effects and reduced allergic reactions by 40 percent. Story

According to results presented at the International Liver Congress, the first hepatitis C vaccine could be on its way. Phase I testing showed that the T-cell vaccine had strong immunogenicity without liver immunopathology. Release

Vaccine Market

Philip Morris has purchased a minority stake in Medicago for $9 million. Medicago uses tobacco leaves to create various influenza vaccines. News

Baruch Blumberg, a Nobel Prize-winner and discoverer of the hepatitis B vaccine, died this week at the age of 85. More than 1 billion doses of hepatitis B vaccines have been distributed since they became commercially available in 1982. Article

The editors of R&D Directions magazine have named Novavax's VLP influenza vaccine one of the top "100 great investigational drugs in development." Novavax release

A physician in Orleans County, NY, has admitted he received $80,000 in insurance payments for free children's vaccines. Dr. Ghulam Mustafa will be sentenced Aug. 5 for making false statements in a healthcare matter, a felony. Report

Two of the Democratic Republic of Congo's 11 provinces will begin distributing pneumoccocal vaccine doses as part of the Global Alliance for Vaccines and Immunization's expanded vax program. Report

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan